back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2025-09-11 13:25 Tx date 2025-09-11 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Mullally, William Hogan
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$56,250
+75,000 vol $0.75 each |
525,000 | |
| Filed 2025-08-01 08:20 Tx date 2025-07-30 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Mullally, William Hogan
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$48,000
+64,000 vol $0.75 each |
939,000 | |
| Filed 2025-06-12 16:41 Tx date 2025-06-11 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Starr, Christopher
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$154,000
+200,000 vol $0.77 each |
300,000 | |
| Filed 2025-06-12 16:26 Tx date 2025-06-11 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$154,000
+200,000 vol $0.77 each |
950,000 | |
| Filed 2025-06-12 16:24 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares Grant Stock Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-06-12 16:16 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$262,500
+750,000 vol $0.35 each |
750,000 | |
| Filed 2025-06-12 16:10 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-06-12 13:40 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares Grant Stock Options
00 - Opening Balance-Initial SEDI Report
|
200,000 | ||
| Filed 2025-06-12 13:40 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares Grant Stock Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-04-06 11:15 Tx date 2022-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-10-07 20:10 Tx date 2019-05-27 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-10-07 20:06 Tx date 2024-09-26 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSU
56 - Grant of rights
|
+1,000,000 vol |
1,000,000 | |
| Filed 2024-10-07 18:07 Tx date 2019-05-27 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSU
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-10-07 15:38 Tx date 2019-05-27 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-10-07 15:38 Tx date 2019-05-27 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Share Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-05-20 15:40 Tx date 2024-02-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$164.00
+200 vol $0.82 each |
6,770,069 | |
| Filed 2024-05-20 15:39 Tx date 2024-02-05 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$13,120
+16,000 vol $0.82 each |
6,769,869 | |
| Filed 2024-05-20 15:38 Tx date 2023-03-31 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,240
+4,000 vol $0.56 each |
6,753,869 | |
| Filed 2024-05-20 15:37 Tx date 2023-03-29 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Rioux, Patrice
3 - 10% Security Holder of Issuer, 4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$6,360
+12,000 vol $0.53 each |
6,749,869 | |
| Filed 2023-12-18 13:50 Tx date 2023-12-15 |
$TTI
Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) |
Riggins, Brook
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$37,500
+50,000 vol $0.75 each |
1,050,000 |